REGISTER FOR THE 2024 CONFERENCE

Shopping Cart

No products in the cart.

REGISTER FOR THE 2024 CONFERENCE

The Society
Conference and Events
- Conferences
  
  Annual Conference 2025
  
  Abstract Submission 2025
  
  Programme 2025
  
  Congress Information 2025
  
  Register for the Conference ⟶
  
  Join us at the forefront of innovation and collaboration! Secure your spot at the 2025 conference today. Don’t miss this opportunity to connect with industry leaders, engage in insightful discussions, and expand your professional network.
  
  Submit an Abstract 2025 (Opening June 15th)
  Are you ready to share your groundbreaking research and innovative ideas with leading experts in the field? We invite you to submit your abstract for the 2025 conference.
Resources
- Resources
  
  Latest ↗
  
  Cachexia ↗
  
  Sarcopenia ↗
  
  Muscle Wasting ↗
  
  Frailty ↗
  
  Ageing ↗
  
  Nutrition ↗
  
  From the Literature ↗
  
  Cancer Cachexia
  
  Exercise ↗
  
  Videos ↗
  
  Explore our Publications Digest ⟶
  
  Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments.
  
  The Journal of Cachexia, Sarcopenia & Muscle ⟶
  The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed international journal dedicated to publishing both research and clinical materials related to cachexia and sarcopenia from all fields of the life sciences.
Guidelines
Membership

neoplasms

Cachexia

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...

🗓️ 2024-12-16

Cancer-associated_cachexia / Carcinoma,_non-small-cell_lung / CELLS / chemotherapy / Drug_therapy / Immune_checkpoint_inhibitors / Lung / Lung_neoplasms / neoplasms / Small_cell_lung_carcinoma / therapeutics / Treatment_outcome / Weight_loss

Cachexia

Cancer cachexia: multilevel metabolic dysfunction.

Cancer cachexia is a complex metabolic disorder marked by unintentional body weight loss or 'wasting' of body mass, driven by multiple aetiological factors operating at various levels. It is associated with many malignancies and significantly contributes to cancer-related morbidity and...

🗓️ 2024-11-22

Cancer-associated_cachexia / neoplasms / therapeutics

Muscle

Targeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles.

Metastatic progression significantly reduces survival rates and complicates treatment strategies in various cancers. Our study introduces an mRNA therapy for metastasis inhibition by targeting activin A overexpression, a pivotal driver of metastasis and cachexia. Utilizing follistatin mRNA lipid nanoparticles, we...

🗓️ 2024-11-21

📰 Publication: Acs Nano

Activins / cachexia / Carcinoma,_squamous_cell / CELLS / Follistatin / Lipid_nanoparticles / muscles / Nanoparticles / Nanotechnology / Neoplasm_metastasis / neoplasms / Rna,_messenger / Squamous_cell_carcinoma_of_head_and_neck / therapeutics

Cachexia

Comment on 'AWGC2023 Cachexia Consensus as a Valuable Tool for Predicting Prognosis and Burden in Chinese Patients With Cancer' by Xie et al.

🗓️ 2024-10-21

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

neoplasms / Prognosis / Sarcopenia

Muscle

Letter to the Editor-"Risk factors for low muscle mass, malnutrition, and (probable-) sarcopenia in adults with or without a history of cancer in the UK Biobank".

🗓️ 2024-10-10

📰 Publication: Clinical Nutrition

Enteral_nutrition / History / Malnutrition / muscles / neoplasms / Risk_factors / Sarcopenia

Cachexia

Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.

Leptin is a reliable predictive and surrogate marker of the efficacy of multitargeted treatment of cancer cachexia. To the best of our knowledge, no study has assessed the predictive role of biomarkers in establishing the effectiveness of anti-cachectic treatment, which...

🗓️ 2024-10-10

FATIGUE / Hand_strength / Leptin / neoplasms / Quality_of_life / Sarcopenia / therapeutics

Sarcopenia

Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable,...

🗓️ 2024-10-22

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Body_composition / Carcinoma,_non-small-cell_lung / Lung / Lung_neoplasms / MORBIDITY / neoplasms / Phenotype / therapeutics

Cachexia

Cancer cachexia.

🗓️ 2024-10-23

📰 Publication: Bmj-British Medical Journal

Cancer-associated_cachexia / neoplasms

Muscle

Impact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

The association between sarcopenia and postoperative complications has been widely reported in patients with cancer. Yet, the lack of standardized population-specific diagnostic cut-off points and assessments of muscle strength is hampering prospective clinical utilization. Therefore, we aimed to examine the...

🗓️ 2024-10-11

Muscle_strength / muscles / neoplasms / Pancreas / Postoperative_complications / PREVALENCE / Sarcopenia

Cachexia

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...

🗓️ 2024-10-01

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Anorexia / Cancer-associated_cachexia / Carcinoma,_non-small-cell_lung / CELLS / chemotherapy / Drug_therapy / Lung / Lung_neoplasms / neoplasms / Quality_of_life / Sarcopenia / Small_cell_lung_carcinoma / therapeutics

Muscle

Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

The impact of computed tomography-defined sarcopenia on outcomes in head and neck cancer has been well described. Sarcopenic obesity (SO) (depleted muscle mass combined with obesity) may pose a more serious risk than either condition alone. We investigated SO and...

🗓️ 2024-09-30

📰 Publication: British Journal Of Nutrition

Head_and_neck_neoplasms / muscles / neoplasms / Nutritional_physiological_phenomena / Obesity / radiotherapy / Sarcopenia / therapeutics / Tomography / Weight_loss

Cancer Cachexia

Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.

There is inconsistent evidence relating to the effects of megestrol acetate (MA) supplementation on cancer patients suffering from anorexia-cachexia syndrome. This review aimed to examine the dose-response effect of MA supplementation in patients with cancer-associated anorexia/cachexia. Relevant keywords were searched...

🗓️ 2024-06-20

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Acetates / Anorexia / Appetite / bodyweight / Cancer-associatedcachexia / FATIGUE / Megestrol / Megestrolacetate / neoplasms / Qualityoflife / Sarcopenia / Weightgain

Cancer Cachexia

Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi-centre factorial randomized trial.

Physical activity and metformin pharmacotherapy are associated with improved clinical outcomes in breast and colorectal cancer survivors. Myokines are cytokines secreted from skeletal muscle that may mediate these associations. This hypothesis-generating analysis used biospecimens collected from a multi-centre 2 × 2 factorial...

🗓️ 2024-06-18

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Biomarkers / Breast / Colorectalneoplasms / Diabetesmellitus / EXERCISE / Interleukin-15 / Metformin / Multiplechronicconditions / muscles / neoplasms / Randomallocation / Sarcopenia

Cachexia

Exploring the optimal indicator of short-term peridiagnosis weight dynamics to predict cancer survival: A multicentre cohort study.

Body weight and its changes have been associated with cancer outcomes. However, the associations of short-term peridiagnosis weight dynamics in standardized, clinically operational time frames with cancer survival remain largely unknown. This study aimed to screen for and evaluate the...

🗓️ 2024-04-21

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Cohortstudies / DIAGNOSIS / Kaplan-meierestimate / neoplasms / Sarcopenia / Survivalanalysis / Weightgain / Weightloss

Cachexia

Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.

Low skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment-related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM and treatment-related toxicities among adults with haematologic malignancies remains unclear....

🗓️ 2024-04-01

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

B-lymphocytes / Lymphoma,b-cell / Lymphoma,largeb-cell,diffuse / Muscle,Skeletal / muscles / neoplasms / Progression-freesurvival / Sarcopenia / therapeutics

Cachexia

Co-morbid sarcopenia and low bone mineral density in young paediatric cancer survivors.

Sarcopenia and low areal bone mineral density (aBMD) are prevalent musculoskeletal complications after paediatric cancer treatment. However, their relationship has not been examined in young paediatric cancers survivors. This study aimed to evaluate aBMD differences according to sarcopenia status and...

🗓️ 2024-08-20

📰 Publication: Journal Of Cachexia Sarcopenia And Muscle

Bonedensity / Cancersurvivors / muscles / Musclestrength / neoplasms / Sarcopenia / therapeutics

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!